期刊文献+

硼替佐米与阿糖胞苷联用对K562细胞增殖和凋亡的影响 被引量:1

Effect of bortezomib and arabinoside on proliferation and apoptosis of K562 cell
原文传递
导出
摘要 目的探讨蛋白酶体抑制剂硼替佐米(Bor)单独或联合阿糖胞苷(Ara—C)对髓系白血病细胞系K562细胞增殖、凋亡的影响,并分析可能的作用机制。方法以20nmol/L的Bor、0.2μg/ml的Ara—C分别单独处理以及不同序贯方式联合处理K562细胞48h后,MTT法检测细胞生长抑制率;流式细胞术检测细胞凋亡率。并在两药分别单独处理6h后用sP免疫组化法分析细胞NF—KB活性及流式细胞术检测细胞周期的变化。结果不同方式联合用药组细胞生长抑制率与细胞凋亡率均高于两药分别单独处理组(P〈0.01),而且在各联合用药组中,先加入Ara—C预处理6h后再序贯加入Bor组的细胞生长抑制率和细胞凋亡率分别为(81.5±4.0)%和(29.2±3.1)%,均高于先加入Bor预处理6h后序贯Ara—C组[(54.1±4.2)%、(18.7±3.5)%]和同时加入组[(66.2±2.8)%、(21.1±2.2)%](P〈0.01)。Bor单独处理细胞6h,细胞NF—κB活性减低,细胞阻滞于G2/M期;Ara—C单独处理细胞6h,NF—KB活性增高,G1期细胞明显增多。结论Bor呵有效抑制K562细胞增殖,并诱导其凋亡,与Ara—C联合,这种效应显著增强,尤以Ara—C预处理后序贯Bor组影响最大。Ara—C预处理后,对NF—κB及细胞周期的影响可能是发挥更大协同效应的原因。 Objective To investigate the effect of bortezomib (Bor) alone and in combination with arabinoside (Ara-C) on proliferation and apoptosis of leukemia cell line K562. Methods K562 ceils were treated with 20 nmol/L Bor and 0.2 μg/ml Ara-C alone and in combination for 48 h. MTT was used to study the inhibitory effects on cell growth and the apoptosis rate was analysed by flow cytometry. After K562 cells treated with 20 nmol/L Bor or 0.2 μg/ml Ara-C for 6 h, the activity of NF-κB was analyzed by SP immuno- histochemistry and cell cycle by flow cytometry. Results The inhibition and apoptosis rates of K562 cells in combination groups were higher than those in the two single treatment groups (P 〈 0. 01 ) , especially in the combined treatment group in which K562 cells were treated first with Ara-C for 6 h then with Bor combined, the inhibition and apoptosis rates were the highest [ (81.5 ± 4.0)% and (29.2± 3. 1 )%, respectively] ( P 〈 0.01 ). In the other two combined groups in which the cells were treated with Bor for 6 h then with Ara- C combined, or treated with the two drugs simultaneously, the inhibition and apoptosis rates were (54.1 ± 4.2)% and (18.7±3.5)%, and (66.2±2.8)% and (21.1±2.2)%, respectively. Treatment ofK562 cells with 20 nmoL/l, Bor for 6 h, the activity of NF-KB was decreased significantly, and the cells were appar- ently arrested in GJM phase, and treatment with 0.2 μg/ml Ara-C in the same manner, the activity of NF- KB was increased significantly, and the cells were apparently arrested in G1 phase. Conclusions Bor can effectively inhibit K562 cell proliferation, and indueed its apoptosis. This effect was enhanced signifieantly when in combination with Ara-C. Pretreatment of K562 ceils with Ara-C lead to the increased activity of NF- κB and the fraction of G1 phase cells.
作者 陆世丰 陆勤
出处 《中华血液学杂志》 CAS CSCD 北大核心 2010年第1期42-45,共4页 Chinese Journal of Hematology
关键词 硼替佐米 阿糖胞苷 K562细胞 细胞周期 NF—κB Bortezomib Arabinoside K562 cell line Cell cycle NF-κB
  • 相关文献

参考文献7

  • 1Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia, 2006,20 : 1341-1352.
  • 2Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 2005,105:3058-3065.
  • 3Dai Y, Rahmani M, Pei XY, et al. Bortezomib and flavopirldol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 2004, 104: 509- 518.
  • 4Rajkmar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol, 2005, 23: 630-639.
  • 5许小平,史剑慧,张宗梁,张劲松,程文英.阿糖胞苷诱导NF-κB活化与白血病细胞凋亡的关系[J].中国癌症杂志,2003,13(2):106-108. 被引量:5
  • 6Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol, 2006,58 : 13-23.
  • 7Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med, 1999,5:412-417.

二级参考文献9

  • 1Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341 :implications for systemic nuclear factor-kappa B inhibition [ J ].Cancer Res,2001,61 ( 9 ) :3535-3540.
  • 2Tao Y, Williams-Skipp C, Scheinman RI. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis [ J ]. J Biol Chem, 2001,276 ( 4 ) : 2329-2332.
  • 3Furuya S,Takayama F, Mimaki Y, et al. Cytotoxic activity of steroidal saponins against human oral tumor cell lines [ J ].Anticancer Res, 2000,20(6B) :4189-4194.
  • 4Feuillard J, Schuhmacher M, Kohanna S, et al. Inducible loss of NF-κB activity is associated with apoptosis and bcl-2 downregulation in Epstein-Barr virus-transformed B lymphocytes [ J ].Blood, 2000,95(6) :2068-2075.
  • 5Berenson JR, Ma HM, Vescio R. The role of nuclear factorkappa B in the biology and treatment of multiple myeloma[ J ].Semin Oncol, 2001,28 ( 6 ) :626- 633.
  • 6Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB [ J ]. Nat Med, 1999,5(4) :412-417.
  • 7Waddick KG, Uckun FM. Innovative treatment programs against cancer: Ⅱ. Nuclear factor-kappa B (NF-kappaB) as a molecular target [ J ]. Biochem Pharmacol, 1999,57 ( 1 ) : 9 -17.
  • 8史剑慧,许小平,程文英,罗伟华,王健民,丁训杰.白血病细胞p53和bcl-2表达与化疗药物诱导凋亡的关系[J].中华内科杂志,2000,39(3):181-184. 被引量:8
  • 9许小平,吕书晴,居小萍,陈莉,王健民.人白血病细胞系在胸腺缺陷裸鼠体内致瘤机制研究[J].中华血液学杂志,2002,23(5):258-260. 被引量:4

共引文献4

同被引文献14

  • 1Li Y, Deng Z, Zhu J, et al. Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CDT+ cells. Acta Haematol, 2014, 132(2):172-176.
  • 2Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun, 2013, 435(1): 52-57.
  • 3Reis FR, Vasconcelos FC, Pereira DL,et al.Survivin and P-glycoprotein are associated and highly, expressed in late phase chronic myeloid leukemia. Oncol 1Lep, 2011, 26(2):471-478.
  • 4Nakahara T, Takeuchi M, Kinoyama I,YM 155, a novel small- molecule survivin suppressant, induces regression of established human hormone- refractory prostate tumor xenografts. Cancer Res, 2007,67(17): 8014-8021.
  • 5Yamanaka K, Nakahara T, Yamauchi T, et al. Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models. Clin Cancer Res, 2011,17(16):5423-5431.
  • 6Park DG. Antichemosensitizing effect of resveratrol in" cotreatment with oxaliplatin in HCT116 colon cancer cell. Ann Surg Treat Res, 2014,86(2):68-75.
  • 7Kaneko N, Mitsuoka K, Amino N, et al.Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. Chn Cancer tkes,2014, 20(7):1814-1822.
  • 8Kelb/RJ, Thomas A, Rajah A, et al. A phase I/II study ofsepantronium bromide (YM155, survivin suppressor) with paclitaxel and carbophtin in patients with advanced non-small-cell lung cancer. Ann Oncol,2013, 24(10):2601-2606.
  • 9Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer,2012, 158(12):3128-3134.
  • 10Wang YF,Zhang W,HE KF, et al. Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis,2014,19(4):748-758.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部